Back to results
US 2026/0174834 A1Published application
Low dose il-6 formulations and methods of use thereof
AssigneeSonnet Biotherapeutics, Inc.
InventorsJohn K. CINI, Himanshu GADGIL, Shilpa GADGIL, Nildip CHAUHAN, Varda KOLAPKAR
Life of this patent
Estimating the term…
Abstract
The present disclosure provides an IL-6 formulation, comprising about 40 μg/mL to about 2 mg/ml IL-6, about 5 to about 15 mM histidine, about 5 to about 15 mg/mL glycine, about 40 to about 60 mg/mL trehalose, about 0.1 to about 0.3 mg/mL polysorbate 20, and about 1 to about 1000 μM DTPA, wherein the formulation has a pH of about 6.0 to about 8.0. Such formulations may be useful to treat and/or prevent a disease or disorder in a subject in need thereof.
Claims23
An IL-6 formulation, comprising:
- about 40 μg/mL to about 2 mg/mL IL-6;
- about 5 to about 15 mM histidine;
- about 5 to about 15 mg/mL glycine;
- about 40 to about 60 mg/mL trehalose;
- about 0.1 to about 0.3 mg/mL polysorbate 20;
- and
- about 1 to about 1000 μM DTPA,
- wherein the formulation has a pH of about 6.0 to about 8.0.
5 more elements
An IL-6 formulation, comprising:
- 40 to about 240 μg/mL human IL-6;
- 10 mM histidine;
- 10 mg/mL glycine;
- 50 mg/mL trehalose;
- 0.2 mg/mL polysorbate 20;
- and
- 50 μM DTPA,
- wherein the formulation has a pH of about 7.0.
5 more elements
Dependencies are inferred from the claim text.